Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Protalix BioTherapeutics (PLX) Assets Average (2016 - 2025)

Protalix BioTherapeutics has reported Assets Average over the past 14 years, most recently at $82.3 million for Q4 2025.

  • Quarterly results put Assets Average at $82.3 million for Q4 2025, up 21.95% from a year ago — trailing twelve months through Dec 2025 was $82.3 million (up 21.95% YoY), and the annual figure for FY2025 was $77.9 million, down 1.32%.
  • Assets Average for Q4 2025 was $82.3 million at Protalix BioTherapeutics, up from $80.4 million in the prior quarter.
  • Over the last five years, Assets Average for PLX hit a ceiling of $105.5 million in Q2 2021 and a floor of $56.2 million in Q4 2022.
  • Median Assets Average over the past 5 years was $78.0 million (2021), compared with a mean of $78.1 million.
  • Biggest five-year swings in Assets Average: tumbled 38.85% in 2022 and later skyrocketed 52.9% in 2023.
  • Protalix BioTherapeutics' Assets Average stood at $78.6 million in 2021, then fell by 28.41% to $56.2 million in 2022, then skyrocketed by 52.9% to $86.0 million in 2023, then decreased by 21.52% to $67.5 million in 2024, then rose by 21.95% to $82.3 million in 2025.
  • The last three reported values for Assets Average were $82.3 million (Q4 2025), $80.4 million (Q3 2025), and $76.2 million (Q2 2025) per Business Quant data.